Skip to content

Alumis Inc. ALMS Cash ratio

Cash ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Amgen logo
AmgenAMGN
0.0×
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-4.2×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
1.3×+0.6×
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
0.7×+0.2×
Immunome logo
ImmunomeIMNM
21.3×+12.9×

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

Based on the most recent quarter.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s cash ratio?
Alumis Inc. (ALMS) reported cash ratio of 0.9× in Q1 2026.
How has Alumis Inc.'s cash ratio changed year-over-year?
Alumis Inc.'s cash ratio decreased by 57.6% year-over-year, from 2.1× to 0.9×.
What is the long-term trend for Alumis Inc.'s cash ratio?
Over 2 years (2023 to 2025), Alumis Inc.'s cash ratio has grown at a -25.5% compound annual growth rate (CAGR), from 2.2× to 1.2×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.